Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse model

Caroline Schoenherr(Medizinische Hochschule Hannover), Melanie Ricke‐Hoch(Medizinische Hochschule Hannover)
Frontiers in Molecular Medicine
January 6, 2025
10.3389/fmmed.2024.1487526
Cited by 0

Related Papers

Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease
|PLoS ONE|2021|89
Long-Term Follow-up in Peripartum Cardiomyopathy Patients with Contemporary Treatment: Low Mortality, High Cardiac Recovery, but Significant Cardiovascular Co-Morbidities
|European Journal of Heart Failure|2019|81
Stable depletion of RUNX1-ETO in Kasumi-1 cells induces expression and enhanced proteolytic activity of Cathepsin G and Neutrophil Elastase
|PLoS ONE|2019|6